258 related articles for article (PubMed ID: 28350808)
21. Amyloidogenic light chains impair plasma cell survival.
Pick M; Lebel E; Elgavish S; Benyamini H; Nevo Y; Hertz R; Bar-Tana J; Rognoni P; Merlini G; Gatt ME
Haematologica; 2023 Dec; 108(12):3359-3371. PubMed ID: 37381778
[TBL] [Abstract][Full Text] [Related]
22. Light chain amyloidosis - current findings and future prospects.
Baden EM; Sikkink LA; Ramirez-Alvarado M
Curr Protein Pept Sci; 2009 Oct; 10(5):500-508. PubMed ID: 19538145
[TBL] [Abstract][Full Text] [Related]
23. Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy.
Wall JS; Williams AD; Foster JS; Richey T; Stuckey A; Macy S; Wooliver C; Campagna SR; Tague ED; Farmer AT; Lands RH; Martin EB; Heidel RE; Kennel SJ
Proc Natl Acad Sci U S A; 2018 Nov; 115(46):E10839-E10848. PubMed ID: 30377267
[TBL] [Abstract][Full Text] [Related]
24. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes.
Harris DL; King E; Ramsland PA; Edmundson AB
J Mol Recognit; 2000; 13(4):198-212. PubMed ID: 10931557
[TBL] [Abstract][Full Text] [Related]
25. Identification of two principal amyloid-driving segments in variable domains of Ig light chains in systemic light-chain amyloidosis.
Brumshtein B; Esswein SR; Sawaya MR; Rosenberg G; Ly AT; Landau M; Eisenberg DS
J Biol Chem; 2018 Dec; 293(51):19659-19671. PubMed ID: 30355736
[TBL] [Abstract][Full Text] [Related]
26. Amyloid formation in light chain amyloidosis.
Ramirez-Alvarado M
Curr Top Med Chem; 2012; 12(22):2523-33. PubMed ID: 23339305
[TBL] [Abstract][Full Text] [Related]
27. Comparison of IGLV2-14 light chain sequences of patients with AL amyloidosis or multiple myeloma.
Berghaus N; Schreiner S; Poos AM; Raab MS; Goldschmidt H; Mai EK; Salwender HJ; Bernhard H; Thurner L; Müller-Tidow C; Weinhold N; Hegenbart U; Schönland SO; Huhn S
FEBS J; 2023 Sep; 290(17):4256-4267. PubMed ID: 37097223
[TBL] [Abstract][Full Text] [Related]
28. A model for amyloid fibril formation in immunoglobulin light chains based on comparison of amyloidogenic and benign proteins and specific antibody binding.
Khurana R; Souillac PO; Coats AC; Minert L; Ionescu-Zanetti C; Carter SA; Solomon A; Fink AL
Amyloid; 2003 Jun; 10(2):97-109. PubMed ID: 12964417
[TBL] [Abstract][Full Text] [Related]
29. AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis.
Manabe S; Iwasaki C; Hatano M; Kametani F; Yazaki M; Nitta K; Nagata M
BMC Nephrol; 2018 Nov; 19(1):337. PubMed ID: 30466387
[TBL] [Abstract][Full Text] [Related]
30. Proteotoxicity in cardiac amyloidosis: amyloidogenic light chains affect the levels of intracellular proteins in human heart cells.
Imperlini E; Gnecchi M; Rognoni P; Sabidò E; Ciuffreda MC; Palladini G; Espadas G; Mancuso FM; Bozzola M; Malpasso G; Valentini V; Palladini G; Orrù S; Ferraro G; Milani P; Perlini S; Salvatore F; Merlini G; Lavatelli F
Sci Rep; 2017 Nov; 7(1):15661. PubMed ID: 29142197
[TBL] [Abstract][Full Text] [Related]
31. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.
Klimtchuk ES; Prokaeva TB; Spencer BH; Gursky O; Connors LH
Amyloid; 2017 Jun; 24(2):115-122. PubMed ID: 28632419
[TBL] [Abstract][Full Text] [Related]
32. Recruitment of human light chain proteins by synthetic fibrils is dependent on disease state and may be used to predict amyloidogenic propensity.
Martin EB; Williams A; Wooliver C; Heidel RE; Adams S; Dunlap J; Ramirez-Alvarado M; Blancas-Mejia L; Kennel SJ; Wall JS
Amyloid; 2017 Mar; 24(sup1):24-25. PubMed ID: 28434355
[No Abstract] [Full Text] [Related]
33. Molecular Mechanism of Pathogenesis and Treatment Strategies for AL Amyloidosis.
Ikura H; Endo J; Kitakata H; Moriyama H; Sano M; Fukuda K
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35683015
[TBL] [Abstract][Full Text] [Related]
34. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine.
Palladini G; Russo P; Bosoni T; Verga L; Sarais G; Lavatelli F; Nuvolone M; Obici L; Casarini S; Donadei S; Albertini R; Righetti G; Marini M; Graziani MS; Melzi D'Eril GV; Moratti R; Merlini G
Clin Chem; 2009 Mar; 55(3):499-504. PubMed ID: 19131635
[TBL] [Abstract][Full Text] [Related]
35. Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.
Martin DJ; Ramirez-Alvarado M
Amyloid; 2010 Sep; 17(3-4):129-36. PubMed ID: 21077798
[TBL] [Abstract][Full Text] [Related]
36. Nephrotoxic potential of Bence Jones proteins.
Solomon A; Weiss DT; Kattine AA
N Engl J Med; 1991 Jun; 324(26):1845-51. PubMed ID: 1904132
[TBL] [Abstract][Full Text] [Related]
37. Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis.
Brancaccio D; Ghiggeri GM; Braidotti P; Garberi A; Gallieni M; Bellotti V; Zoni U; Gusmano R; Coggi G
J Am Soc Nephrol; 1995 Oct; 6(4):1262-70. PubMed ID: 8589295
[TBL] [Abstract][Full Text] [Related]
38. Fatal amyloid formation in a patient's antibody light chain is caused by a single point mutation.
Kazman P; Vielberg MT; Pulido Cendales MD; Hunziger L; Weber B; Hegenbart U; Zacharias M; Köhler R; Schönland S; Groll M; Buchner J
Elife; 2020 Mar; 9():. PubMed ID: 32151314
[TBL] [Abstract][Full Text] [Related]
39. Effect of single point mutations in a form of systemic amyloidosis.
Bhavaraju M; Hansmann UH
Protein Sci; 2015 Sep; 24(9):1451-62. PubMed ID: 26105812
[TBL] [Abstract][Full Text] [Related]
40. Mass spectrometry characterization of light chain fragmentation sites in cardiac AL amyloidosis: insights into the timing of proteolysis.
Lavatelli F; Mazzini G; Ricagno S; Iavarone F; Rognoni P; Milani P; Nuvolone M; Swuec P; Caminito S; Tasaki M; Chaves-Sanjuan A; Urbani A; Merlini G; Palladini G
J Biol Chem; 2020 Dec; 295(49):16572-16584. PubMed ID: 32952127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
